MedTrace Logo

Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

NCT03189576 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2023-05-26

No results posted yet for this study

Summary

Circulating tumour DNA (ctDNA) is a promising tool when monitoring the residual disease in colorectal cancer (CRC). Current staging procedures are insufficient to identify the patient cohort at high risk, who might benefit from additional adjuvant therapy.

We will show that the assessment of ctDNA is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. Minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.

Conditions

Interventions

DIAGNOSTIC_TEST

blood draw

Sponsors & Collaborators

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Pirkko-Liisa Kellokumpu-Lehtinen, professor · Tampere University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2023-08-30
Completion
2023-08-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03189576 on ClinicalTrials.gov